TEVA analyst estimates
Teva (TEVA) analyst ratings, the average price target and its range, and every firm's latest call.
TEVA analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 15, 2026 | Barclays | Teva price target raised to $47 from $42 at Barclays | $47.00 |
| Oct 12, 2026 | Raymond James | Teva Pharma (TEVA) PT Raised to $50 at JPMorgan | $50.00 |
| Sep 23, 2026 | Oppenheimer | Teva initiated with an Outperform at Oppenheimer | $50.00 |
| Sep 9, 2026 | Leerink Partners | Teva initiated with an Outperform at Leerink | $45.00 |
| Sep 4, 2026 | UBS | Teva Pharma (TEVA) PT Raised to $48 at UBS | $48.00 |
| Aug 12, 2026 | Barclays | Teva price target raised to $42 from $40 at Barclays | $42.00 |
| Jul 28, 2026 | Piper Sandler | Teva price target raised to $44 from $42 at Piper Sandler | $44.00 |
| May 6, 2026 | Barclays | Teva price target raised to $40 from $38 at Barclays | $40.00 |
| Apr 30, 2026 | UBS | Teva price target raised to $42 from $36 at UBS | $42.00 |
| Apr 30, 2026 | Piper Sandler | Teva price target raised to $42 from $41 at Piper Sandler | $42.00 |
| Mar 4, 2026 | Piper Sandler | Teva Pharma (TEVA) PT Raised to $41 at Piper Sandler; 'Much To Be Bullish About' | $41.00 |
| Jan 30, 2026 | Barclays | Teva price target raised to $38 from $35 at Barclays | $38.00 |
| Jan 29, 2026 | Scotiabank | Teva price target raised to $40 from $35 at Scotiabank | $40.00 |
| Jan 7, 2026 | Truist Financial | Teva price target raised to $36 from $32 at Truist | $36.00 |
| Jan 6, 2026 | Jefferies | Teva price target raised, named a top 2026 idea at Jefferies | $40.00 |
- 0 firms rate TEVA: 0 buy, 0 hold, 0 sell.
- The average price target is $47.33 from 6 analysts, from $44.00 to $50.00.
Updated 2026-11-02 17:14 UTC